PepGen announces CONNECT program updates
PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...
Cullinan reports zipalertinib study met primary endpoint
Taiho Pharmaceutical and Taiho Oncology reported that a Phase 1/2 study of the drug zipalertinib met its primary endpoint of overall response rate in a study of EGFR lung cancer patients. The drug was ...
PepGen continues trials for DMD treatment, addresses safety concerns
BOSTON - PepGen Inc. (NASDAQ: PEPG), a biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological diseases, is progressing with its CONNECT clinical program for ...
marketinference20h
Cullinan Therapeutics Succeeds in NSCLC Trial
Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COGT), a biotechnology company focused on ...
News Medical on MSN21h
Study identifies potential gain of function mutation in retinoblastoma
A new research paper was published in Volume 16 of Genes & Cancer on January 20, 2025, entitled, "Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation." ...